服務熱線
021-60498804
| Cat. Number | P2815 |
| Chemical Name | P2815 PHENYLBUTYRATE SODIUM 1716-12-7 |
| CAS Number | 1716-12-7 |
| Mol. Formula | C10H11O2Na |
| Mol. Weight | 186.18 |
| Qty 1 |
1g |
| Qty 2 | 25g |
| Appearance | White crystalline powder |
| Application Notes | ≥98% |
| Synonym | Buphenyl, Sodium 4-phenylbutyrate, Tributyrate |
| Melting Pt. | 214-220°C |
| Solubility | Soluble in water, ethanol, DMSO. |
| Storage condition | Ambient |
| References | Phenylbutyrate is an inhibitor of histone deacetylase (HDAC) that exhibits neuroprotective and anticancer chemotherapeutic activities. In cellular and animal models of pancreatic cancer, phenylbutyrate inhibits cellular proliferation and tumor growth. This compound is clinically used to treat urea cycle disorders, as it allows excretion of excess nitrogen waste. In animal models of Alzheimer’s disease, phenylbutyrate prevents neuronal loss and normalizes brain pathology. ReferencesCuadrado-Tejedor M, Ricobaraza AL, Torrijo R, et al. Phenylbutyrate is a multifaceted drug that exerts neuroprotective effects and reverses the Alzheimer′s disease-like phenotype of a commonly used mouse model. Curr Pharm Des. 2013;19(28):5076-84. PMID: 23448463. Dovzhanskiy DI, Hartwig W, Lázár NG, et al. Growth inhibition of pancreatic cancer by experimental treatment with 4-phenylbutyrate is associated with increased expression of Connexin 43. Oncol Res. 2012;20(2-3):103-11. PMID: 23193916. Iannitti T, Palmieri B. Clinical and experimental applications of sodium phenylbutyrate. Drugs R D. 2011 Sep 1;11(3):227-49. PMID: 21902286. Batshaw ML, MacArthur RB, Tuchman M. Alternative pathway therapy for urea cycle disorders: twenty years later. J Pediatr. 2001 Jan;138(1 Suppl):S46-54; Erratum in: J Pediatr 2002 Apr;140(4):490. PMID: 11148549. |
下一個：ROMIDEPSIN上一個：MYCOPHENOLIC ACID |
|
Copyright ? 2022 上?；菡\生物科技有限公司
滬ICP備2021037845號-6
